Your Support Can Help Us Make a Difference in 2025!
As we near the end of 2024, we want to reflect on the incredible progress we've made together in raising excessive sweating awareness as well as advancing education and care for people living with hyperhidrosis. We also want to invite you to be part of the impactful work we have planned for 2025 and beyond.
Exclusive Early Access to Sofdra – Limited-Time Telehealth Offer!
We’re excited to offer IHhS subscribers exclusive, early access to Sofdra™ (sofpironium) topical gel, a new FDA-approved hyperhidrosis treatment! Read the full story to learn more about this limited-time offer.
A Special Day for a Special Cause
This Giving Tuesday, please support us. Your donations directly help to keep our information and support services free and accessible to everyone, everywhere.
Sofdra™ Gel Gains FDA Approval.
For the first time in six years there is a new prescription, at-home, and self-applied treatment for primary axillary hyperhidrosis (extreme sweating in the armpits). Sofdra™ was recently approved by the U.S. FDA, and we’ve got the most complete and up-to-date information on it here.
WHO Expands Global Access to Hyperhidrosis Education: A Game-Changer for Medical Professionals and Patients
In a significant step toward improving the lives of individuals living with hyperhidrosis, the World Health Organization (WHO) has partnered with the International Hyperhidrosis Society (IHhS) to make two groundbreaking courses available to healthcare providers and patients around the world.
Latest Blogs
